A novel opportunity for targeted drug delivery to the brain.
Gaillard
P J
PJ
to-BBB technologies BV, Einsteinweg 55, Leiden, The Netherlands.
de Boer
A G
AG
D000818:Animals; D001253:Astrocytes / Q000166:cytology / Q000378:metabolism; D001426:Bacterial Proteins / Q000737:chemistry / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D002417:Cattle; D018920:Coculture Techniques; D016503:Drug Delivery Systems / Q000379:methods*; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism; D006168:Guinea Pigs; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism*
D001426:Bacterial Proteins; C587883:HBEGF protein, human; C587885:Hbegf protein, rat; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D011956:Receptors, Cell Surface; C028581:CRM197 (non-toxic variant of diphtheria toxin)